来自官方财务报表的收入、利润与现金流历史。
阿斯利康公司是一家生物制药公司，专注于处方药的发现、开发、制造和商业化。该公司提供 Imjudo、Datroway、Iressa、Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Crestor、Andexxa、Onglyza、Symlin、XIGDUO XR、Atacand、Atacand HCT、Atacand Plus、Farxiga/Forxiga、Plendil、Modip、Splendil、 Munobal、Flodil、Tenormin、Tenormine、Prenormine、Atenol、Zestril、Brilinta/Brilique、Komboglyze、Qtern、Wainua、Byetta、Lokelma、Seloken ZOK、Toprol-XL、Betaloc ZOK、XIGDUO、Accolate、Accoleit、Vanticon、Bricanyl Respules、Eklira Genuair/Tudorza/Bretaris、 Pulmicort Turbuhaler、Symbicort Turbuhaler、Airsupra、Bricanyl Turbuhaler、Fasenra、Rhinocort、Tezspire、Bevespi
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $61.4B | $58.7B | $54.1B | $45.8B | $44.4B | $37.4B | $26.6B | $24.4B | $22.1B | $22.5B | $23.0B | $24.7B | $26.5B | $25.8B | $28.0B | $33.6B | $33.3B | $32.8B | $31.6B | $29.6B | $26.5B |
| 毛利 | $50.2B | $48.1B | $43.9B | $37.5B | $32.0B | $25.0B | $21.3B | $19.5B | $17.2B | $18.1B | $18.9B | $20.1B | $20.7B | $20.5B | $22.6B | $27.6B | $26.9B | $27.0B | $25.0B | $23.1B | $20.9B |
| 毛利率% | 81.9% | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% | 81.2% | 78.0% | 79.6% | 80.7% | 82.1% | 80.8% | 82.4% | 79.1% | 78.3% | 79.0% |
| 营业利润（EBIT） | $14.0B | $13.7B | $10.0B | $8.2B | $3.8B | $1.1B | $5.2B | $2.9B | $3.4B | $3.7B | $4.9B | $4.1B | $2.1B | $3.7B | $8.1B | $12.8B | $11.5B | $11.5B | $9.1B | $8.1B | $8.2B |
| 营业利润率% | 22.8% | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% | 16.7% | 8.1% | 14.4% | 29.1% | 38.1% | 34.5% | 35.2% | 28.9% | 27.4% | 31.0% |
| 净利 | $10.4B | $10.3B | $7.0B | $6.0B | $3.3B | $112M | $3.2B | $1.3B | $2.2B | $3.0B | $3.5B | $2.8B | $1.2B | $2.6B | $6.2B | $9.9B | $8.1B | $7.5B | $6.1B | $5.6B | $6.0B |
| 净利润率 % | 17.0% | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% | 11.4% | 4.6% | 9.9% | 22.3% | 29.5% | 24.2% | 22.9% | 19.3% | 18.9% | 22.8% |
| EBITDA | — | $19.8B | $15.4B | $13.4B | $9.1B | $5.1B | $8.1B | $6.7B | $7.1B | $6.6B | $7.3B | $7.0B | $5.5B | $8.3B | $10.7B | $15.4B | $14.7B | $13.9B | $12.6B | $9.9B | $9.6B |
| 每股收益（EPS） | $6.69 | $6.57 | $4.50 | $3.81 | $2.11 | $0.16 | $4.87 | $2.05 | $3.40 | $4.74 | $5.53 | $4.47 | $1.95 | $4.08 | $9.87 | $14.51 | $11.14 | $10.37 | $8.40 | $7.47 | $7.70 |
| 已发行股数 (M) | — | 1,562M | 1,563M | 1,562M | 1,560M | 714M | 656M | 650M | 634M | 634M | 633M | 632M | 632M | 627M | 632M | 684M | 723M | 725M | 726M | 749M | 785M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 AZN 交互式查看器。 /companies/us/AZN
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms